Skip to content

JBIO JBIO Interest Expense

Discontinued — last reported Q1 '26

Interest Expense at other companies

Travere Therapeutics, Inc. logo
Travere Therapeutics, Inc.TVTX
$2.3M-19.5%
Vera Therapeutics logo
Vera TherapeuticsVERA
$1.82M+1.7%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
$803K-30.1%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
$3.46M+529%
TG Therapeutics logo
TG TherapeuticsTGTX
$7.67M+13.5%
Johnson & Johnson logo
Johnson & JohnsonJNJ
$272M+33.3%

Other financials

Income statement

See full
Operating income-$43.4M-85.8%
Net income-$40.4M-5.8%
EPS (diluted)-$0.57+95.3%

Balance sheet

See full
Cash & equivalents$55.1M+24.6%
Total debt$808.0K+159%
Total equity$296.5M+455%
Total assets$319.4M+312%

Cash flow

See full
Operating cash flow-$24.1M-28.4%
CapEx$3.0K
Free cash flow-$33.7M

Valuation

See full
Market cap$1.33B+318%
Enterprise value$1.28B

Returns & leverage

See full
Return on equity-132.5%+120pp
Debt / equity
Current ratio14.3×-17.7×

Where this comes from

Reported directly by JBIO in its filing.

Tagged under the XBRL concept us-gaap:InterestIncomeExpenseNonoperatingNet.

The official record: JBIO’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about JBIO's interest expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is JBIO's interest expense?
JBIO (JBIO) reported interest expense of $3.1M in Q1 2026.
How has JBIO's interest expense changed year-over-year?
JBIO's interest expense increased by 404.4% year-over-year, from $615K to $3.1M.
What is the long-term trend for JBIO's interest expense?
Over 4 years (2021 to 2025), JBIO's interest expense has grown at a 230.8% compound annual growth rate (CAGR), from $65K to $7.78M.
What does interest expense mean?
Cost of borrowing — interest paid or accrued on bonds, bank loans, credit facilities, finance leases, and other debt obligations.